ProShare Advisors LLC decreased its position in Amarin Corporation PLC (NASDAQ:AMRN) by 3.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 135,234 shares of the biopharmaceutical company’s stock after selling 4,942 shares during the quarter. ProShare Advisors LLC’s holdings in Amarin Corporation PLC were worth $545,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in AMRN. Wells Fargo & Company MN increased its position in shares of Amarin Corporation PLC by 4.8% in the first quarter. Wells Fargo & Company MN now owns 32,801 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 1,500 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Amarin Corporation PLC by 27.1% during the 1st quarter. JPMorgan Chase & Co. now owns 35,590 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 7,580 shares in the last quarter. Perkins Capital Management Inc. boosted its stake in shares of Amarin Corporation PLC by 20.3% during the 2nd quarter. Perkins Capital Management Inc. now owns 41,500 shares of the biopharmaceutical company’s stock valued at $167,000 after purchasing an additional 7,000 shares in the last quarter. Airain ltd boosted its stake in shares of Amarin Corporation PLC by 382.9% during the 2nd quarter. Airain ltd now owns 87,122 shares of the biopharmaceutical company’s stock valued at $351,000 after purchasing an additional 69,081 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. boosted its stake in shares of Amarin Corporation PLC by 1.4% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 143,650 shares of the biopharmaceutical company’s stock valued at $460,000 after purchasing an additional 2,050 shares in the last quarter. Hedge funds and other institutional investors own 37.76% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “ProShare Advisors LLC Has $545,000 Holdings in Amarin Corporation PLC (AMRN)” was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.watchlistnews.com/proshare-advisors-llc-has-545000-holdings-in-amarin-corporation-plc-amrn/1609445.html.

A number of equities research analysts have recently weighed in on AMRN shares. Jefferies Group LLC reaffirmed a “buy” rating and set a $5.00 target price on shares of Amarin Corporation PLC in a research note on Monday, June 12th. Cantor Fitzgerald set a $5.00 target price on shares of Amarin Corporation PLC and gave the company a “buy” rating in a research note on Monday, June 12th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Amarin Corporation PLC in a research note on Wednesday, June 28th. BidaskClub raised shares of Amarin Corporation PLC from a “hold” rating to a “buy” rating in a research note on Friday, June 30th. Finally, Zacks Investment Research raised shares of Amarin Corporation PLC from a “sell” rating to a “hold” rating in a research note on Monday, July 3rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $7.20.

Shares of Amarin Corporation PLC (AMRN) opened at 3.53 on Thursday. Amarin Corporation PLC has a 52 week low of $2.65 and a 52 week high of $4.47. The stock’s 50 day moving average is $3.25 and its 200-day moving average is $3.32. The company’s market cap is $955.90 million.

Amarin Corporation PLC (NASDAQ:AMRN) last posted its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.01. The company had revenue of $44.95 million during the quarter, compared to analysts’ expectations of $40.35 million. The company’s quarterly revenue was up 37.0% on a year-over-year basis. During the same period in the prior year, the business earned ($0.07) EPS. On average, equities analysts anticipate that Amarin Corporation PLC will post ($0.21) earnings per share for the current year.

Amarin Corporation PLC Profile

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Institutional Ownership by Quarter for Amarin Corporation PLC (NASDAQ:AMRN)

Receive News & Ratings for Amarin Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corporation PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.